Back to Directory

Intermittent Hypoxic-Hyperoxic Training

IHHT, Hypoxia-Hyperoxia Therapy, IHT

Visual ViewRaw Data

Meta Information

ID:intermittent-hypoxic-hyperoxic-training
Name:Intermittent Hypoxic-Hyperoxic Training
Schema Version:1.5

Alternate Names

  • IHHT
  • Hypoxia-Hyperoxia Therapy
  • IHT

Active Compound

null

Intervention Type

protocol

Delivery

Route:
inhalation
Scope:
  • systemic

Regulatory Status

  • us:unregulated_device
  • eu:unregulated_device

Indication

Focus:
healthspan
Description:
Aims to improve mitochondrial function, cellular resilience, and cardiovascular health by exposing the body to alternating periods of low and high oxygen.

Typical Protocol

  • Sessions typically last 40-60 minutes and are performed 2-3 times per week.
  • Each cycle involves 3-7 minutes of breathing hypoxic air (9-15% oxygen) followed by 2-5 minutes of hyperoxic air (30-36% oxygen).
  • A standard course consists of 10-20 sessions over several weeks.

Expected Cost Mean

Low Cost:
5000
High Cost:
25000
Cost Type:
equipment
Description:
Cost of a home-use IHHT device; not typically covered by insurance.

Summary

IHHT involves breathing alternating cycles of low-oxygen (hypoxic) and high-oxygen (hyperoxic) air through a specialized device. This process is thought to trigger adaptive responses similar to high-altitude training, primarily by stimulating the removal of damaged mitochondria (mitophagy) and the creation of new, healthy ones (mitochondrial biogenesis). The goal is to enhance cellular energy production, improve oxygen utilization, and increase resilience to oxidative stress, thereby supporting overall healthspan.

Purpose

Enhances mitochondrial function and cellular resilience via oxygen modulation.

Card Summary

A non-invasive protocol using a device to deliver alternating low and high oxygen air, aiming to boost mitochondrial health and cellular stress resistance.

Drug Class

null

Drugs In Class

Empty Array

Impact

Score:
4.5
Justification:
Targets mitochondrial function, a key aging hallmark, but lacks large-scale human healthspan data.

Evidence

Grade:
B
Score:
5.5
Justification:
Small human trials show biomarker improvements, but large healthspan-focused RCTs are lacking.

Safety

Score:
3.5
Justification:
Generally safe but poses risks for individuals with specific cardiovascular or respiratory conditions.

Flags

  • Contraindicated for individuals with severe hypertension, heart failure, epilepsy, or acute infections.
  • Must be performed with proper equipment that monitors blood oxygen saturation (SpO2).
  • Potential for mild side effects like headache, dizziness, or fatigue post-session.
  • Quality and calibration of consumer-grade devices can vary significantly.

Verdict

A promising but developing tool for enhancing mitochondrial health and resilience.

Created

2026-05-06T16:40:55.210511Z

Ai Model

Gemini 2.5 Pro (High)